bluuebunny/crossref_metadata_2025_split huggingface dataset:
DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma
Authors: Wang Lin , Liu Weihai , Tang Hengtao , Xie Xianbiao , Zou Changye , Wang Yongqian , Gao Zhenhua , Yin Junqiang 
Published: April 2017

AbstractOsteosarcoma is an extremely aggressive primary malignant bone tumor of childhood. Collapsin response mediator proteins (CRMPs), which are highly expressed in the developing nervous system, were recently shown to be associated with cancer development. However, the relationship between DRP5 (CRMP5) and osteosarcoma has not been evaluated. In this study, we investigated the role of DRP5 in the regulation of osteosarcoma growth. DRP5 mRNA and protein levels were significantly upregulated in human osteosarcoma cell lines and associated with increased migration and invasion. Genetic knockdown of DRP5 markedly suppressed the expression of matrix metalloproteinase (MMP)‐2 and MMP‐9. DRP5 silencing significantly inhibited osteosarcoma cell growth in vitro and in a xenograft mouse model in vivo. Microarray immunohistochemical analysis of osteosarcoma specimens and Kaplan–Meier analysis showed that patients with high DRP5 protein expression had shorter overall survival than those with low DRP5 levels. Taken together, these results suggest that DRP5 plays a critical role in the regulation of osteosarcoma and could be a potential therapeutic target and prognostic factor in osteosarcoma.
Diffusion of digital breast tomosynthesis among women in primary care: associations with insurance type
Authors: Clark Cheryl R. , Tosteson Tor D. , Tosteson Anna N. A. , Onega Tracy , Weiss Julie E. , Harris Kimberly A. , Haas Jennifer S. 
Published: April 2017

AbstractDigital breast tomosynthesis (DBT) has shown potential to improve breast cancer screening and diagnosis compared to digital mammography (DM). The FDA approved DBT use in conjunction with conventional DM in 2011, but coverage was approved by CMS recently in 2015. Given changes in coverage policies, it is important to monitor diffusion of DBT by insurance type. This study examined DBT trends and estimated associations with insurance type. From June 2011 to September 2014, DBT use in 22 primary care centers in the Dartmouth ‐Brigham and Women's Hospital Population‐based Research Optimizing Screening through Personalized Regimens research center (PROSPR) was examined among women aged 40–89. A longitudinal repeated measures analysis estimated the proportion of DBT performed for screening or diagnostic indications over time and by insurance type. During the study period, 93,182 mammograms were performed on 48,234 women. Of these exams, 16,506 DBT tests were performed for screening (18.1%) and 2537 were performed for diagnosis (15.7%). Between 2011 and 2014, DBT utilization increased in all insurance groups. However, by the latest observed period, screening DBT was used more frequently under private insurance (43.4%) than Medicaid (36.2%), Medicare (37.8%), other (38.6%), or no insurance (32.9%; P < 0.0001). No sustained differences in use of DBT for diagnostic testing were seen by insurance type. DBT is increasingly used for breast cancer screening and diagnosis. Use of screening DBT may be associated with insurance type. Surveillance is required to ensure that disparities in breast cancer screening are minimized as DBT becomes more widely available.
A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas
Authors: Wang Fengze , Zhang Hui , Xue Yang , Wen Jiao , Zhou Jun , Yang Xinjie , Wei Jianhua 
Published: April 2017

AbstractHuman papillomavirus (HPV), the causal factor of cervical cancers, was closely linked to the etiology and prognosis of oropharyngeal squamous cell carcinoma (OPSCC), but its role in oral squamous cell carcinoma (OSCC) was unclear. In addition, few researches based on Chinese population were documented. Hence, we sought to investigate the relationship of HPV marker P16 protein to the clinicopathological parameters and survival of OPSCC and OSCC patients systematically to assess the influence of ethnic, regional difference on HPV susceptibility. Specimens from 93 OPSCC patients and 95 OSCC patients were recut, and P16 immunohistochemistry (IHC) was performed. Moreover, survival analysis was conducted to confirm the independent factors that influenced the prognosis. The P16 results were positive in 25.8% and 9.5% of patients with OPSCC and OSCC, respectively. The overall survival (OS) of HPV‐positive OPSCC patients was significantly longer than that of HPV‐negative OPSCC patients (P = 0.004). Conversely, statistical significance was not observed regarding the OS of OSCC patients (P = 0.343). Cox regression analysis indicated that T stage and P16 status were independent factors that affected the prognosis of OPSCC patients, and the smoking index influenced the prognosis of OSCC patients. Among OPSCC patients who received radiochemotherapy (RCT), HPV‐positive patients had a better survival rate than their HPV‐negative counterparts (P = 0.015). Conversely, no significant difference was observed between HPV‐positive and HPV‐negative OSCC patients who received RCT (P = 0.237). P16 is a credible surrogate by which to define HPV status. HPV expression had a favorable effect on OPSCC patients as opposed to their OSCC counterparts in this single center population‐based study.
Risk and associated risk factors of hospitalization for specific health problems over time in childhood cancer survivors: a medical record linkage study
Authors: Font‐Gonzalez Anna , Feijen Elizabeth (Lieke) A.M. , Geskus Ronald B. , Dijkgraaf Marcel G.W. , van der Pal Helena J.H. , Heinen Richard C. , Jaspers Monique W. , van Leeuwen Flora E. , Reitsma J.B. (Johannes) , Caron Hubert N. , Sieswerda Elske , Kremer Leontien C. 
Published: April 2017

AbstractChildhood cancer survivors (CCS) experience higher hospitalization rates compared to the general population for neoplasms, circulatory diseases, endocrine/nutritional/metabolic diseases and eye disorders. We studied trends in hospitalization rates and associated patient and treatment‐specific risk factors for diagnosis subgroups among these four diseases. We performed medical record linkage of a ≥5‐year CCS cohort with national registers, and obtained a random reference sample matched on age, gender and calendar year per CCS. For each diagnosis subgroup we compared hospitalization rates and trends over time in CCS and the reference population. Further, we analyzed risk factors for hospitalizations within the four CCS diagnosis groups. We used multivariate Poisson regression for all models. We retrieved hospitalization data from 1382 CCS and 26,583 reference persons. CCS had increased hospitalization rates for almost all diagnosis subgroups examined. Hospitalization rates for endocrine/nutritional/metabolic diseases appeared to increase with longer time since primary cancer diagnosis up to 30 years after primary cancer diagnosis. Survivors initially treated with radiotherapy had increased hospitalization rates for neoplasms (P < 0.001), those initially treated with anthracyclines (2.5 [1.1–5.5]) and radiotherapy to thorax and/or abdomen (9.3 [2.4–36.6]) had increased hospitalization rates for diseases of the circulatory system, and those initially treated with radiotherapy to head and/or neck had increased hospitalization rates for endocrine/nutritional/metabolic diseases (6.7 [3.5–12.7]) and diseases of the eye (3.6 [1.5–8.9]). Our study highlights that long‐term health problems resulting in hospitalizations are still clinically relevant later in life of CCS. The identified treatment‐related risk factors associated with hospitalizations support targeted follow‐up care for these risk groups of CCS.
A large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK‐positive non‐small‐cell lung cancer
Authors: Chen Gang , Chen Xi , Zhang Yaxiong , Yan Fang , Fang Wenfeng , Yang Yunpeng , Hong Shaodong , Miao Siyu , Wu Manli , Huang Xiaodan , Luo Youli , Zhou Cong , Gong Run , Huang Yan , Zhou Ningning , Zhao Hongyun , Zhang Li 
Published: April 2017

AbstractCrizotinib has achieved astonishing success in advanced non‐small‐cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) rearrangement. However, no real‐world studies described the clinicopathological characteristics and treatment of such patients in China. Patients were consecutively collected from Sun Yat‐sen University Cancer Center. Chi‐square test was applied to explore the relationship between ALK fusion status and metastasis sites. Kaplan–Meier methods and multivariable analyses were used to estimate progression‐free survival (PFS). A total of 291 advanced NSCLC patients (ALK (+), N = 97; both ALK & epidermal growth factor receptor (EGFR) (‐), N = 194) were enrolled. The occurrence of brain metastasis in ALK‐positive patients was significantly higher than double‐negative ones both at baseline (26.5% vs. 16.5%, P = 0.038) and during treatment (25.8% vs. 11.9%, P = 0.003), but opposite for pleural effusion (6.2% vs. 26.9%, P < 0.001 at baseline; 3.1% vs. 10.3%, P = 0.031 during treatment). ALK‐positive patients of 53.6% used crizotinib, whereas others only received chemotherapy (37.1%) or supportive care (9.3%). Usage of crizotinib prolonged PFS compared with chemotherapy in ALK‐positive patients (median PFS 17.6 m vs. 4.8 m, P < 0.001). ALK‐positive NSCLC had more brain metastasis and less pleural effusion than double‐negative ones. Crizotinib showed better PFS than chemotherapy in advanced ALK‐positive NSCLC at any line. However, half advanced ALK‐positive patients never received crizotinib, which was grim and need improving.
A cross‐sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women
Authors: Wu Qiongyan , Zhao Xiumin , Fu Yunfeng , Wang Xinyu , Zhang Xiaofei , Tian Xun , Cheng Bei , Lu Bingjian , Yu Xiao , Lan Suqiu , Lu Weiguo , Ma Ding , Cheng Xiaodong , Xie Xing 
Published: April 2017

AbstractCytology‐based cervical cancer screening is restricted because of a lack of cytologists. Thus, HPV‐based instead of cytology‐based screening may be a more suitable strategy in China. Here, we assessed the effectiveness of HPV testing (Cobas® 4800 Test, Roche) and HPV‐based programs to detect high‐grade cervical intraepithelial neoplasia (CIN) or cancer compared with cytology (Thinprep, Hologic) and cytology‐based programs through a cross‐sectional study in 11,064 Chinese women aged 21–65 years who were enrolled from Longyou County in Zhejiang Province, China. The rates of HPV positivity and cytology abnormality were 9.8% and 6.1%, respectively. The HPV positivity rate had two age peaks, 21–24 (15.4%) and 60–65 (14.4%) years. According to adjusted data, HPV testing demonstrated significantly higher sensitivity and negative predictive value (NPV) than cytology for detecting CIN2 or worse (90.0% vs. 66.7%, 99.9% vs. 99.5%), and there was an acceptable specificity (91.3%) and positive predictive value (PPV, 12.5%). Furthermore, primary HPV testing with type 16/18 genotyping showed the highest sensitivity (78.6%) and NPV (99.7%) among four screening strategies, and there was similar specificity (96.8%) and PPV (23.9%) compared with co‐testing screening to detect CIN2+, while there were fewer colposcopies (4.2) and tests (106.3) performed than with co‐testing and primary cytology screening to detect a case of high‐grade CIN. The differences in effectiveness were approximately similar when CIN3+ was the identifying target. Our findings suggest that primary HPV testing with type 16/18 genotyping has a higher sensitivity and NPV, possesses optimal cost/effectiveness in the first round of screening and is a feasible strategy of cervical cancer screening for Chinese women.
A rare cause of mechanical bowel obstruction: ingested vinyl glove. Unexpected diagnosis at laparoscopy
Authors: Smerieri Nazareno , Barbieri Italo , Fumagalli Matteo , Luppi Davide , Lanaia Andrea , Bonilauri Stefano 
Published: April 2017

Key Clinical MessageThe report suggests that, when the patient's history, clinical examination, and findings do not lead to a clear diagnosis in case of an acute abdomen, a laparoscopic approach, that has both, diagnostic and therapeutic value, is advised.
Interstitial lung disease of infancy caused by a new NKX2‐1 mutation
Authors: Safi Khalid H. , Bernat John A. , Keegan Catherine E , Ahmad Ayesha , Hershenson Marc B. , Arteta Manuel 
Published: April 2017

Key Clinical MessagePatients with personal or family history of congenital hypothyroidism, and/or neurological findings that also have chronic respiratory symptoms may have a mutation in the NKX2.1 gene as the unifying cause of their disease. Brain–lung–thyroid disease is the ensuing condition, which although rare, needs to be part of the differential diagnosis.
Syndrome of progressive bone marrow failure and pancreatic insufficiency remains cryptic despite whole exome sequencing: variant of Shwachman‐Diamond syndrome or new condition?
Authors: Fadus Matthew C. , Rush Eric T. , Lettieri Christina K. 
Published: April 2017

Key Clinical MessageThis case underscores the difficulty in diagnosis of bone marrow failure disorders, as the presentation of disease can be inconsistent, complicated by complex and ever‐expanding genetic etiologies. A patient who presents with bone marrow failure and pancreatic insufficiency raises the question of Shwachman‐Diamond syndrome (SDS) or a new condition which resembles SDS.
Peripartum cardiomyopathy, what if your patient plans to reconceive?
Authors: Al Bannay Rashed , Husain Aysha , AlJufairi Zainab 
Published: April 2017

Key Clinical MessagePatients with peripartum cardiomyopathy (PPCM) often express a desire to conceive again, and the risk of relapse in future pregnancies should be disclosed. No consensus is available that can determine that risk. Adequate contractile reserve, evidenced by a stress echocardiogram (exercise or dobutamine), can identify those with lower relapse risk.
“Chronic myelogenous leukemia in primary blast crisis” rather than “de novo BCR‐ABL1‐positive acute myeloid leukemia”
Authors: Pastoret Cedric , Houot Roch 
Published: April 2017

Key Clinical MessageDifferentiating chronic myelogenous leukemia in primary blast crisis (CML‐BC) from de novo BCR‐ABL1‐positive acute myeloid leukemia (AML) is a diagnostic challenge with therapeutic consequences. In our case, a basophilia, the presence of the Philadelphia chromosome in all metaphases and the strict exclusion of molecular hallmarks of AML lead us to retain the diagnosis of CML‐BC rather than BCR‐ABL1+ AML.
Highly Efficient Atom‐Economic Synthesis of Chiral Bis(indolyl)methanes Bearing Quaternary Stereogenic Carbon Centers
Authors: Zhang Yan , Zhang Si‐Xiang , Fu Li‐Na , Guo Qi‐Xiang 
Published: April 2017

AbstractA highly efficient atom‐economic method for the preparation of chiral 3,3′‐bis(indolyl)methanes (3,3′‐BIMs) was developed. A chiral phosphoric acid (1 mol %) was found to promote the formation of structurally divers BIMs with quaternary stereogenic carbon centers in excellent yields with excellent enantioselectivities. Control experiments indicated that the simultaneous formation of two hydrogen bonds between the catalyst and the substrate was the key factor to obtain a good stereoselective outcome.
A Ratiometric Near‐Infrared Fluorogen for the Real Time Visualization of Intracellular Redox Status during Apoptosis
Authors: Saranya Giridharan , Anees Palapuravan , Joseph Manu M. , Maiti Kaustabh K. , Ajayaghosh Ayyappanpillai 
Published: April 2017

AbstractDirect monitoring of apoptotic progression is a major step forward for the early assessment of therapeutic efficacy of certain treatments and the accurate evaluation of the spread of a disease. Here, the regulatory role of glutathione (GSH) is explored as a potential biomarker for tracking apoptosis. For this purpose, a near‐ infrared (NIR) squaraine dye is introduced that is capable of sensing GSH in a ratiometric manner by switching its emission from NIR (690 nm) to visible region (560 nm). The favorable biocompatible attributes of the probe facilitated the real‐time monitoring of apoptotic process in line with the conventional apoptotic assay. Furthermore, the robust nature of the probe was utilized for the quantitative estimation of GSH during different stages of apoptosis. Through this study, an easy and reliable method of assaying apoptosis is demonstrated, which can provide valuable insights in translational clinical research.
A Blueprint for Software Architectures in Process Optimization
Authors: Fricke Armin , Schöneberger Jan Christian 
Published: April 2017

AbstractHow to use software effectively and efficiently in the chemical, pharmaceutical and life science industries is one of the central questions in Process Optimization. The paper shows in five examples from chemical engineering how various programs connect to a first principle process simulator through the existing interfaces. It also shows how the functionality of a process simulator can be enhanced. Through the application programming interface (CC‐API), the objects are re‐used beyond the boundaries of the flow sheeting program CHEMCAD.
Optimization‐Based Process Synthesis Based on a Commercial Flowsheet Simulator
Authors: Janus Tim , Foussette Christophe , Urselmann Maren , Tlatlik Stephen , Gottschalk Axel , Emmerich Michael , Bäck Thomas , Engell Sebastian 
Published: April 2017

AbstractAnhand von Simulationen mit einem kommerziellen Fließbildsimulator werden optimierte Fließbilder generiert. Da der Simulator keine expliziten Gleichungen und keine Ableitungen zur Verfügung stellt, wird ein memetischer Algorithmus eingesetzt. Dieser kombiniert einen evolutionären Algorithmus mit einer lokalen ableitungsfreien Suche. Es werden diskrete Designvariablen und kontinuierliche Parameter optimiert. Anhand eines Fallbeispiels wird das Verhalten des Optimierers demonstriert. Von Experten vorgeschlagene Startlösungen können deutlich verbessert werden, allerdings ist der Rechenzeitbedarf für komplexere Fließbilder noch relativ hoch.
Synthesis of Qinghaosu Analogues from Dihydroqinghao Aldehyde: A Dark Singlet Oxygen Approach
Authors: Liu Xunshen , Chen Huijun , Xu Zejun , Wu Yikang , Liu Bo 
Published: April 2017

AbstractA range of qinghaosu (artemisinin) analogues were synthesized from modified dihydroqinghao acid/aldehyde using dark singlet oxygen to trigger off the key step of the trioxane formation. The newly accessed 1,2,4‐trioxanes featured a side chain extended from the carbon corresponding to the lactone carbonyl group of qinghaosu through a stable carbon‐carbon single bond instead of an acetal oxygen‐carbon bond in most similar analogues in the literature. Biotin and various amines were also connected to the qinghaosu core, respectively, through such a linear tether in efforts to develop hybrids and potentially useful probes in search of the in vivo targets.
A Time‐Resolved FRET Cell‐Based Binding Assay for the Apelin Receptor
Authors: Valencia Christel , Dujet Céline , Margathe Jean‐François , Iturrioz Xavier , Roux Thomas , Trinquet Eric , Villa Pascal , Hibert Marcel , Dupuis Elodie , Llorens‐Cortes Catherine , Bonnet Dominique 
Published: April 2017

AbstractAnalogues of apelin‐13 carrying diverse spacers and an ad hoc DY647‐derived fluorophore were designed and synthesized by chemoselective acylation of α‐hydrazinopeptides. The resulting probes retain very high affinity and efficacy for both the wild‐type and SNAP‐tagged apelin receptor (ApelinR). They give a time‐resolved FRET (TR‐FRET) signal with rare‐earth lanthanides used as donor fluorophores grafted onto the SNAP‐tagged receptor. This specific signal allowed the validation of a binding assay with a high signal‐to‐noise ratio. In such an assay, the most potent sub‐nanomolar fluorescent probe was found to be competitively displaced by the endogenous apelin peptides with binding constants similar to those obtained in a classical radioligand assay. We have thus validated the first TR‐FRET cell‐based binding assay for ApelinR with potential high‐throughput screening applications.
Cytologic features and clinical implications of undifferentiated carcinoma with osteoclastic giant cells of the pancreas: An analysis of 15 cases
Authors: Reid Michelle D. , Muraki Takashi , HooKim Kim , Memis Bahar , Graham Rondell P. , Allende Daniela , Shi Jiaqi , Schaeffer David F. , Singh Remmi , Basturk Olca , Adsay Volkan 
Published: April 2017

BACKGROUNDThe cytologic features of undifferentiated pancreatic carcinoma with osteoclastic giant cells (UOC) are rarely described.METHODSCytologic and clinicopathologic characteristics in 15 UOC fine‐needle aspiration (FNA) specimens were analyzed.RESULTSFNA specimens were obtained from 6 men and 8 women with a mean age of 65 years who had UOCs (head, n = 7; body, n = 3; and tail, n = 4) with a mean radiologic size 7.3 cm, and some had a cystic component (n = 9). Three cell types (osteoclastic giant cells, pleomorphic tumor giant cells, and spindled/histiocytoid cells) were observed in 12 of 15 specimens (80%); and pancreatic ductal adenocarcinoma (PDAC) was present in 11 specimens. FNA diagnoses were UOC (n = 6), PDAC (n = 5), poorly differentiated carcinoma (n = 2), “suspicious for neoplasm” (n = 1), and “negative” (n = 1). Five of 5 specimens with osteoclastic giant cells were positive for cluster of differentiation 68 (CD68) (a glycoprotein that binds to low‐density lipoprotein). Pleomorphic tumor giant cells and spindled/histiocytoid cells were positive for pancytokeratin (6 of 7 specimens), CAM5.2 (2 of 3 specimens), and epithelial membrane antigen (2 of 2 specimens). INI‐1 protein expression was retained in 3 of 3 specimens. The Ki‐67 labeling index was assessed in 3 specimens and was 12%, 18%, and 40%; 4 of 12 resected UOCs were pure, and 8 were mixed with PDAC. One resection specimen had intraductal papillary mucinous neoplasm, and 2 had mucinous cystic neoplasms. The median overall survival (OS) of patients who had UOCs identified on FNA was 8 months (6 died [OS, 8 months; range, 2‐22 months], and 8 remained alive [OS, 3 months; range, 1‐27 months]), which was similar to the survival of 74 patients who had PDACs identified on FNA (OS, 15 months; P = .279) but worse than that of the 27 patients with UOCs who did not undergo FNA (OS, 92 months; P = .0135).CONCLUSIONSThe 3 classical UOC cell types are identifiable on FNA, making cytologic diagnosis possible if considered in the differential. A PDAC component is often also observed. The survival advantage of UOC over pure PDAC appears to be negated by FNA and requires further investigation. Cancer Cytopathol 2017;125:563–75. © 2017 American Cancer Society.